|
1
|
Kolak A, Kamińska M, Sygit K, Budny A,
Surdyka D, Kukielka-Budny B and Burdan F: Primary and secondary
prevention of breast cancer. Ann Agric Environ Med. 24:549–553.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yedjou CG, Tchounwou PB, Payton M, Miele
L, Fonseca DD, Lowe L and Alo RA: Assessing the racial and ethnic
disparities in breast cancer mortality in the United States. Int J
Environ Res Public Health. 14:E4862017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang W, Song XW and Zhao CH: Roles of
programmed cell death protein 5 in inflammation and cancer
(Review). Int J Oncol. 49:1801–1806. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pan Z, Jing W, He K, Zhang L and Long X:
SATB1 is correlated with progression and metastasis of breast
cancers: A meta-analysis. Cell Physiol Biochem. 38:1975–1983. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang M, Zhang C, Song Y, Wang Z, Wang Y,
Luo F and Xu Y, Zhao Y, Wu Z and Xu Y: Mechanism of immune evasion
in breast cancer. Onco Targets Ther. 10:1561–1573. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu H, Chen Y, Wu S, Song F, Zhang H and
Tian M: Molecular imaging using PET and SPECT for identification of
breast cancer subtypes. Nucl Med Commun. 37:1116–1124. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xing L, He Q, Wang YY, Li HY and Ren GS:
Advances in the surgical treatment of breast cancer. Chin Clin
Oncol. 5:342016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
De A, Kuppusamy G and Karri VVSR: Affibody
molecules for molecular imaging and targeted drug delivery in the
management of breast cancer. Int J Biol Macromol. 107:906–919.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Matos Do Canto L, Marian C, Varghese RS,
Ahn J, Da Cunha PA, Willey S, Sidawy M, Rone JD, Cheema AK, Luta G,
et al: Metabolomic profiling of breast tumors using ductal fluid.
Int J Oncol. 49:2245–2254. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Quispe-Soto ET and Calaf GM: Effect of
curcumin and paclitaxel on breast carcinogenesis. Int J Oncol.
49:2569–2577. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang N, Zhou TC, Lei XX, Wang C, Yan M,
Wang ZF, Liu W, Wang J, Ming KH, Wang BC, et al: Inhibition of
Sonic Hedgehog signaling pathway by thiazole antibiotic
thiostrepton attenuates the CD44+/CD24-stem-like population and
sphere-forming capacity in triple-negative breast cancer. Cell
Physiol Biochem. 38:1157–1170. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Canfeld K, Wells W, Geradts J, Kinlaw WB,
Cheng C and Kurokawa M: Inverse association between MDM2 and HUWE1
protein expression levels in human breast cancer and liposarcoma.
Int J Clin Exp Pathol. 9:6342–6349. 2016.PubMed/NCBI
|
|
13
|
Santa Mina D, Brahmbhatt P, Lopez C, Baima
J, Gillis C, Trachtenberg L and Silver JK: The case for
prehabilitation prior to breast cancer treatment. PM R. 9
(Suppl):S305–S316. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mo CH, Gao L, Zhu XF, Wei KL, Zeng JJ,
Chen G and Feng ZB: The clinicopathological significance of UBE2C
in breast cancer: A study based on immunohistochemistry, microarray
and RNA-sequencing data. Cancer Cell Int. 17:832017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gomulkiewicz A, Jablonska K, Pula B,
Grzegrzolka J, Borska S, Podhorska-Okolow M, Wojnar A, Rys J,
Ambicka A, Ugorski M, et al: Expression of metallothionein 3 in
ductal breast cancer. Int J Oncol. 49:2487–2497. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xiong DD, Lv J, Wei KL, Feng ZB, Chen JT,
Liu KC, Chen G and Luo DZ: A nine-miRNA signature as a potential
diagnostic marker for breast carcinoma: An integrated study of
1,110 cases. Oncol Rep. 37:3297–3304. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shen SQ, Huang LS, Xiao XL, Zhu XF, Xiong
DD, Cao XM, Wei KL, Chen G and Feng ZB: miR-204 regulates the
biological behavior of breast cancer MCF-7 cells by directly
targeting FOXA1. Oncol Rep. 38:368–376. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li CY, Xiong DD, Huang CQ, He RQ, Liang
HW, Pan DH, Wang HL, Wang YW, Zhu HW and Chen G: Clinical value of
miR-101-3p and biological analysis of its prospective targets in
breast cancer: A study based on The Cancer Genome Atlas (TCGA) and
bioinformatics. Med Sci Monit. 23:1857–1871. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Efferth T, Li PC, Konkimalla VS and Kaina
B: From traditional Chinese medicine to rational cancer therapy.
Trends Mol Med. 13:353–361. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang S, Penchala S, Prabhu S, Wang J and
Huang Y: Molecular basis of traditional Chinese medicine in cancer
chemoprevention. Curr Drug Discov Technol. 7:67–75. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qi F, Li A, Zhao L, Xu H, Inagaki Y, Wang
D, Cui X, Gao B, Kokudo N, Nakata M and Tang W: Cinobufacini, an
aqueous extract from Bufo bufo gargarizans Cantor, induces
apoptosis through a mitochondria-mediated pathway in human
hepatocellular carcinoma cells. J Ethnopharmacol. 128:654–661.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yin PH, Liu X, Qiu YY, Cai JF, Qin JM, Zhu
HR and Li Q: Anti-tumor activity and apoptosis-regulation
mechanisms of bufalin in various cancers: New hope for cancer
patients. Asian Pac J Cancer Prev. 13:5339–5343. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen KK, Anderson RC and Henderson FG:
Comparison of cardiac action of bufalin, cinobufotalin, and
telocinobufagin with cinobufagin. Proc Soc Exp Biol Med.
76:372–374. 1951. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cheng L, Chen YZ, Peng Y, Yi N, Gu XS, Jin
Y and Bai XM: Ceramide production mediates cinobufotalin-induced
growth inhibition and apoptosis in cultured hepatocellular
carcinoma cells. Tumour Biol. 36:5763–5771. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kai S, Lu JH, Hui PP and Zhao H:
Pre-clinical evaluation of cinobufotalin as a potential anti-lung
cancer agent. Biochem Biophys Res Commun. 452:768–774. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lv C, Wu X, Wang X, Su J, Zeng H, Zhao J,
Lin S, Liu R, Li H, Li X and Zhang W: The gene expression profiles
in response to 102 traditional Chinese medicine (TCM) components: A
general template for research on TCMs. Sci Rep. 7:3522017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Harryman WL, Pond E, Singh P, Little AS,
Eschbacher JM, Nagle RB and Cress AE: Laminin-binding integrin gene
copy number alterations in distinct epithelial-type cancers. Am J
Transl Res. 8:940–954. 2016.PubMed/NCBI
|
|
29
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Thul PJ and Lindskog C: The human protein
atlas: A spatial map of the human proteome. Protein Sci.
27:233–244. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
He RQ, Li XJ, Liang L, Xie Y, Luo DZ, Ma
J, Peng ZG, Hu XH and Chen G: The suppressive role of miR-542-5p in
NSCLC: The evidence from clinical data and in vivo validation using
a chick chorioallantoic membrane model. BMC Cancer. 17:6552017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Uhlen M, Zhang C, Lee S, Sjöstedt E,
Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, et
al: A pathology atlas of the human cancer transcriptome. Science.
357(pii): eaan25072017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Panosyan EH, Lin HJ, Koster J and Lasky JL
III: In search of druggable targets for GBM amino acid metabolism.
BMC Cancer. 17:1622017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Petrizzo A, Caruso FP, Tagliamonte M,
Tornesello ML, Ceccarelli M, Costa V, Aprile M, Esposito R,
Ciliberto G, Buonaguro FM and Buonaguro L: Identification and
validation of HCC-specific gene transcriptional signature for tumor
antigen discovery. Sci Rep. 6:292582016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu X, Wang X, Fu B, Meng L and Lang B:
Differentially expressed genes and microRNAs in bladder carcinoma
cell line 5637 and T24 detected by RNA sequencing. Int J Clin Exp
Pathol. 8:12678–12687. 2015.PubMed/NCBI
|
|
36
|
Cao L, Zhang Q, Cheng S, Chen Z, Hua Z,
Yang J, Liu D and Cui N: Long non-coding RNAs and genes
contributing to the generation of cancer stem cells in
hepatocellular carcinoma identified by RNA sequencing analysis.
Oncol Rep. 36:2619–2624. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang DW, Yu SY, Cao Y, Yang L, Liu W, Er
XQ, Yao GJ and Bi ZG: Identification of CD20, ECM, and ITGA as
biomarkers for osteosarcoma by integrating transcriptome analysis.
Med Sci Monit. 22:2075–2085. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xu X and Li H: Integrated microRNA-gene
analysis of coronary artery disease based on miRNA and gene
expression profiles. Mol Med Rep. 13:3063–3073. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang Y, Zhang J, Li L, Xu X, Zhang Y, Teng
Z and Wu F: Identification of molecular targets for predicting
colon adenocarcinoma. Med Sci Monit. 22:460–468. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen W, Liu Q, Lv Y, Xu D, Chen W and Yu
J: Special role of JUN in papillary thyroid carcinoma based on
bioinformatics analysis. World J Surg Oncol. 15:1192017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tian W, Liu J, Pei B, Wang X, Guo Y and
Yuan L: Identification of miRNAs and differentially expressed genes
in early phase non-small cell lung cancer. Oncol Rep. 35:2171–2176.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li J, Yang X, Guan H, Mizokami A, Keller
ET, Xu X, Liu X, Tan J, Hu L, Lu Y and Zhang J: Exosome-derived
microRNAs contribute to prostate cancer chemoresistance. Int J
Oncol. 49:838–846. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Song B, Du J, Feng Y, Gao YJ and Zhao JS:
Co-expressed differentially expressed genes and long non-coding
RNAs involved in the celecoxib treatment of gastric cancer: An RNA
sequencing analysis. Exp Ther Med. 12:2455–2468. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang H, Zhang X, Huang J and Fan X:
Identification of key genes and pathways for peri-implantitis
through the analysis of gene expression data. Exp Ther Med.
13:1832–1840. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yu H, Pei D, Chen L, Zhou X and Zhu H:
Identification of key genes and molecular mechanisms associated
with dedifferentiated liposarcoma based on bioinformatic methods.
Onco Targets Ther. 10:3017–3027. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Nicolau CA, Prorock A, Bao Y,
Neves-Ferreira AGDC, Valente RH and Fox JW: Revisiting the
therapeutic potential of Bothrops jararaca venom: Screening for
novel activities using connectivity mapping. Toxins (Basel).
10:E692018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Thillaiyampalam G, Liberante F, Murray L,
Cardwell C, Mills K and Zhang SD: An integrated meta-analysis
approach to identifying medications with potential to alter breast
cancer risk through connectivity mapping. BMC Bioinformatics.
18:5812017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Busby J, Murray L, Mills K, Zhang SD,
Liberante F and Cardwell CR: A combined connectivity mapping and
pharmacoepidemiology approach to identify existing medications with
breast cancer causing or preventing properties. Pharmacoepidemiol
Drug Saf. 27:78–86. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liu Y, Zhao Y, Wei Z, Tao L, Sheng X, Wang
S, Chen J, Ruan J, Liu Z, Cao Y, et al: Targeting thioredoxin
system with an organosulfur compound, diallyl trisulfide (DATS),
attenuates progression and metastasis of triple-negative breast
cancer (TNBC). Cell Physiol Biochem. 50:1945–1963. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liao KF, Chiu TL, Huang SY, Hsieh TF,
Chang SF, Ruan JW, Chen SP, Pang CY and Chiu SC: Anti-cancer
effects of radix angelica sinensis (Danggui) and
N-butylidenephthalide on gastric cancer: Implications for REDD1
activation and mTOR inhibition. Cell Physiol Biochem. 48:2231–2246.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hao J, Jin Z, Zhu H, Liu X, Mao Y, Yang X,
Gao L, Liu D, Chen D and Wu X: Antiestrogenic activity of the
Xi-huang formula for breast cancer by targeting the estrogen
receptor α. Cell Physiol Biochem. 47:2199–2215. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ding X, Yang Q, Kong X, Haffty BG, Gao S
and Moran MS: Radiosensitization effect of Huaier on breast cancer
cells. Oncol Rep. 35:2843–2850. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Browne AL, Charmsaz S, Vareslija D, Fagan
A, Cosgrove N, Cocchiglia S, Purcell S, Ward E, Bane F, Hudson L,
et al: Network analysis of SRC-1 reveals a novel transcription
factor hub which regulates endocrine resistant breast cancer.
Oncogene. 37:2008–2021. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hamurcu Z, Delibasi N, Gecene S, Sener EF,
Dönmez-Altuntas H, Ozkul Y, Canatan H and Ozpolat B: Targeting LC3
and Beclin-1 autophagy genes suppresses proliferation, survival,
migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin
β1/Src signaling in triple negative breast cancer cells. J Cancer
Res Clin Oncol. 144:415–430. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Abdullah C, Korkaya H, Iizuka S and
Courtneidge SA: SRC increases MYC mRNA expression in ER+
breast cancer via mRNA stabilization and inhibition of p53
function. Mol Cell Biol. (pii): MCB.00463-172017.(Epub ahead of
print). View Article : Google Scholar
|
|
56
|
Ocana A, Gil-Martin M, Martin M, Rojo F,
Antolin S, Guerrero A, Trigo JM, Munoz M, Pandiella A, et al: A
phase I study of the SRC kinase inhibitor dasatinib with
trastuzumab and paclitaxel as first line therapy for patients with
HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study.
Oncotarget. 8:73144–73153. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Li Y, Zhou W, Tang K, Chen X, Feng Z and
Chen J: Silencing Aurora A leads to re-sensitization of breast
cancer cells to Taxol through downregulation of SRC-mediated ERK
and mTOR pathways. Oncol Rep. 38:2011–2022. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Subash-Babu P, Li DK and Alshatwi AA: In
vitro cytotoxic potential of friedelin in human MCF-7 breast cancer
cell: Regulate early expression of Cdkn2a and pRb1, neutralize
mdm2-p53 amalgamation and functional stabilization of p53. Exp
Toxicol Pathol. 69:630–636. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Spitzwieser M, Entfellner E, Werner B,
Pulverer W, Pfeiler G, Hacker S and Cichna-Markl M:
Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and
tumor-distant tissues from breast cancer patients. BMC Cancer.
17:2602017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Bi QR, Hou JJ, Qi P, Ma CH, Shen Y, Feng
RH, Yan BP, Wang JW, Shi XJ, Zheng YY, et al: Venenum Bufonis
induces rat neuroinflammation by activiating NF-κB pathway and
attenuation of BDNF. J Ethnopharmacol. 186:103–110. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Engel SR and Grant KA: Neurosteroids and
behavior. Int Rev Neurobiol. 46:321–348. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Li Y, Liu X, Tang H, Yang H and Meng X:
RNA sequencing uncovers molecular mechanisms underlying
pathological complete response to chemotherapy in patients with
operable breast cancer. Med Sci Monit. 23:4321–4327. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zhou L, Gao HF, Liu DS, Feng JY, Gao DD
and Xia W: Gene expression profiling of brain metastatic cell from
triple negative breast cancer: Understanding the molecular events.
Gene. 640:21–27. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Choi HY, Park N, Na JB, Ko ES, Park JY and
Yoo JC: Direct binding of Copine3 with Jab1 activates downstream
ErbB2 signaling and motility in SKBr3 breast cancer cells. Oncol
Rep. 35:1147–1152. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Li Y, Liu X, Tang H, Yang H and Meng X:
RNA sequencing uncovers molecular mechanisms underlying
pathological complete response to chemotherapy in patients with
operable breast cancer. Med Sci Monit. 23:4321–4327. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Yang M, Li H, Li Y, Ruan Y and Quan C:
Identification of genes and pathways associated with MDR in
MCF-7/MDR breast cancer cells by RNA-seq analysis. Mol Med Rep.
17:6211–6226. 2018.PubMed/NCBI
|
|
67
|
Dang YW, Lin P, Liu LM, He RQ, Zhang LJ,
Peng ZG, Li XJ and Chen G: In silico analysis of the potential
mechanism of telocinobufagin on breast cancer MCF-7 cells. Pathol
Res Pract. 214:631–643. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Varga K, Hollósi A, Pászty K, Hegedűs L,
Szakács G, Tímár J, Papp B, Enyedi Á and Padányi R: Expression of
calcium pumps is differentially regulated by histone deacetylase
inhibitors and estrogen receptor alpha in breast cancer cells. BMC
Cancer. 18:10292018. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Chen WY, Wu F, You ZY, Zhang ZM, Guo YL
and Zhong LX: Analyzing the differentially expressed genes and
pathway cross-talk in aggressive breast cancer. J Obstet Gynaecol
Res. 41:132–140. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Trifa F, Karray-Chouayekh S, Jmal E, Jmaa
ZB, Khabir A, Sellami-Boudawara T, Frikha M, Daoud J and
Mokdad-Gargouri R: Loss of WIF-1 and Wnt5a expression is related to
aggressiveness of sporadic breast cancer in Tunisian patients.
Tumour Biol. 34:1625–1633. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Di J, Huang H, Qu D, Tang J, Cao W, Lu Z,
Cheng Q, Yang J, Bai J, Zhang Y and Zheng J: Rap2B promotes
proliferation, migration, and invasion of human breast cancer
through calcium-related ERK1/2 signaling pathway. Sci Rep.
5:123632015. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Lou JS, Yao P and Tsim KWK: Cancer
treatment by using traditional Chinese medicine: Probing active
compounds in anti-multidrug resistance during drug therapy. Curr
Med Chem. 25:5128–5141. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Jiang Y and Gao H: Pharmacophore-based
drug design for potential AChE inhibitors from traditional chinese
medicine database. Bioorg Chem. 76:400–414. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Zheng X, Wu F, Lin X, Shen L and Feng Y:
Developments in drug delivery of bioactive alkaloids derived from
traditional Chinese medicine. Drug Deliv. 25:398–416. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Xia X, Cole SPC, Cai T and Cai Y: Effect
of traditional Chinese medicine components on multidrug resistance
in tumors mediated by P-glycoprotein. Oncol Lett. 13:3989–3996.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Yuan SY, Shiau MY, Ou YC, Huang YC, Chen
CC, Cheng CL, Chiu KY, Wang SS and Tsai KJ: Miconazole induces
apoptosis via the death receptor 5-dependent and
mitochondrial-mediated pathways in human bladder cancer cells.
Oncol Rep. 37:3606–3616. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Roan CJ, Chou CT, Liang WZ, Chang HT, Kuo
DH, Kuo CC, Chen FA, Shieh P and Jan CR: Effect of miconazole on
[Ca2+]i and cytotoxicity in ZR-75-1 human
breast cancer cells. Chin J Physiol. 58:377–384. 2015. View Article : Google Scholar : PubMed/NCBI
|
